Abstract Body

Background: Hepatitis E virus (HEV) incidence in HIV infected patients has not been well established. Studies reporting HEV seroprevalence and incidence in this populations present several methodological limitations such as retrospective analysis and small population samples. As a result, the current magnitude of this emerging disease in this population cannot be established. Therefore, we designed a study to evaluate the incidence of HEV and its clinical implications in HIV infected patients.

Methods: Prospective study in Southern Spain that included HIV-infected patients who were followed up between September 2012 and July 2014. All patients included were tested for anti-HEV IgG using EIA (Wantai HEV-IgG ELISA). All anti-HEV negative patients were prospectively followed-up during 1 year. In these patients an EIA anti-HEV IgG was performed each 6. In those patients with anti-HEV IgG positive, a RT-PCR was performed (amplicube HEV). Clinical and demographic variables were collected at baseline and during the follow-up. Incidence rate was calculated.

Results: Eight-hundred and ninety two patients were included at baseline. Of them, 188 (21.07%) showed positive for anti-HEV IgG, consequently, 704 patients were included in the study. Six-hundred and twenty-one (88.2%) complete the study period. The median follow-up (interquartile range) was 11.96 months (8.52-14.52). Thirty-four (5.4%) patients seroconverted for anti-HEV IgG during the follow-up. This represent an incidence rate of 5.6 cases /100 patients-year (95% CI: 3.8%-7.5%). Among the 34 HEV seroconverted patients, in two (5.8%) HEV-RNA was amplified. Twenty-one patients (61.7%) presented clinical manifestation and/or changes in liver function test at the time of seroconversion. The more frequent clinical manifestations were: fever (11/21; 52.3%), digestive manifestation (12/21; 57.1%), diffuse abdominal pain (10/21; 47.6%) and asthenia (20/21; 95.2%). Among these patients, one (co-infected with Hepatitis B virus in liver cirrhosis stage) presented liver decompensation (ascites) at the moment of the HEV seroconversion. Interestingly, 10 (47.6%) of these patients experienced HIV viral blips during the HEV seroconversion.

Conclusions: HEV present a high prevalence and incidence in HIV infected patients. In the majority of patients, HEV infection curse as a symptomatic disease. In our study, HEV seroconversion was associated with HIV viral blips.